Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out - mintz.com
Federal Circuit affirms the obviousness of Rifaximin polymorph patents, impacting patent protections for certain formulations.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers and generic/ANDA manufacturers involved with Rifaximin formulations. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate assessment required; no specific deadline stated.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The court's ruling undermines the patent protections for Rifaximin polymorphs, potentially allowing for generic competition.
Who it affects
Branded drug makers and generic/ANDA manufacturers involved with Rifaximin formulations.
What you must do
Evaluate the implications of the ruling on current and future product lines related to Rifaximin.
Deadline
Immediate assessment required; no specific deadline stated.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Title V Synthetic Minor Permit Applications: STA Pharmaceutical - dnrec.delaware.gov
- Huons recalls three injectable exports in US over cGMP compliance issue - CHOSUNBIZ - Chosunbiz
- What FDA's AI Warning Letter Tells Us About GMP Accountability - pharmtech.com
- DEA Proposes Rescheduling DORAs - Sleep Review
- Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers - pharmtech.com